Most cited papers from Seagen (United States)

Seagen (United States)

What are the most cited papers from Seagen (United States)?

The most cited paper from Seagen (United States) is "CONFIDENCE LIMITS ON PHYLOGENIES: AN APPROACH USING THE BOOTSTRAP" (Joseph Felsenstein, 1985), with 41,763 citations. Next come "A comprehensive analysis of protein–protein interactions in Saccharomyces cerevisiae" (4,754) and "The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3" (3,417).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 303 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	CONFIDENCE LIMITS ON PHYLOGENIES: AN APPROACH USING THE BOOTSTRAP Joseph Felsenstein · Evolution Open access	Jul 1985	41,763
2	A comprehensive analysis of protein–protein interactions in Saccharomyces cerevisiae Peter H Uetz, Loïc Giot, Gerard Cagney et al. · Nature	Feb 2000	4,754
3	The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 Craig L. Bennett, Jacinda R. Christie, Fred Ramsdell et al. · Nature Genetics	2001	3,417
4	Cases in which Parsimony or Compatibility Methods will be Positively Misleading Joe Felsenstein · Systematic Biology	Dec 1978	2,953
5	VEGF Inhibition and Renal Thrombotic Microangiopathy Vera Eremina, J. Ashley Jefferson, Jolanta Kowalewska et al. · New England Journal of Medicine Open access	12 Mar 2008	1,514
6	Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas Anas Younes, Nancy L. Bartlett, John Paul Leonard et al. · New England Journal of Medicine Open access	3 Nov 2010	1,371
7	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer Rashmi Krishna Murthy et al. · New England Journal of Medicine Open access	11 Dec 2019	1,345
8	Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate Kevin J. Hamblett, Peter D. Senter, Dana F. Chace et al. · Clinical Cancer Research	15 Oct 2004	1,251
9	Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma Thomas B. Powles, Jonathan E. Rosenberg, Guru Sonpavde et al. · New England Journal of Medicine Open access	12 Feb 2021	1,233
10	Development of potent monoclonal antibody auristatin conjugates for cancer therapy Svetlana O. Doronina, Brian E. Toki, Michael Y. Torgov et al. · Nature Biotechnology	30 May 2003	1,215
11	TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease Jane A. Gross, Janet V. Johnston, Sherri Mudri et al. · Nature	Apr 2000	1,183
12	Potent antibody therapeutics by design Paul J. Carter · Nature reviews. Immunology Review	7 Apr 2006	1,104
13	Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Thomas B. Powles et al. · New England Journal of Medicine Open access	6 Mar 2024	1,072
14	Arming antibodies: prospects and challenges for immunoconjugates Anna M. Wu, Peter D. Senter · Nature Biotechnology	Sep 2005	1,051
15	cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity Joseph A. Francisco, Charles G. Cerveny, Damon L. Meyer et al. · Blood	13 May 2003	939
16	A Hidden Markov Model approach to variation among sites in rate of evolution Joe Felsenstein, Gary A. Churchill · Molecular Biology and Evolution	1996	864
17	Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells Farbod Shojaei, Xiumin Wu, Ajay K. Malik et al. · Nature Biotechnology	29 Jul 2007	851
18	Antibody–drug conjugates come of age in oncology Charles Dumontet, Janice M. Reichert, Peter D. Senter et al. · Nature Reviews Drug Discovery Review	12 Jun 2023	845
19	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma Joseph M. Connors et al. · New England Journal of Medicine Open access	10 Dec 2017	792
20	Antibody-Drug Conjugates in Cancer Therapy Eric L. Sievers, Peter D. Senter · Annual Review of Medicine Review	8 Oct 2012	776
21	The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma Peter D. Senter, Eric L. Sievers · Nature Biotechnology	Jul 2012	769
22	Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial Craig H. Moskowitz, Auayporn P. Nademanee, Tamás Masszi et al. · The Lancet Open access	28 Mar 2015	741
23	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Steven M. Horwitz et al. · The Lancet Open access169 authors	3 Dec 2018	739
24	Antibody–drug conjugates: targeted drug delivery for cancer Stephen C. Alley, Nicole M. Okeley, Peter D. Senter · Current Opinion in Chemical Biology Review	20 Jul 2010	659
25	Genetic analysis of ageing: role of oxidative damage and environmental stresses George M. Martin, Steven N. Austad, Thomas E. Johnson · Nature Genetics	May 1996	652
26	Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy Jonathan E. Rosenberg, Peter H. O’Donnell, Arjun Vasant Balar et al. · Journal of Clinical Oncology Open access	29 Jul 2019	649
27	Polyaniline nanofibers: broadening applications for conducting polymers Christina O. Baker, Xinwei Huang, Wyatt C. Nelson et al. · Chemical Society Reviews Review	2017	625
28	[24] Inferring phylogenies from protein sequences by parsimony, distance, and likelihood methods Joseph Felsenstein · Methods in enzymology on CD-ROM/Methods in enzymology Book chapter	1996	614
29	The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin Holly G. Davies, Rebecca J. Richter, Matthew Keifer et al. · Nature Genetics	Nov 1996	602
30	A checkpoint regulates the rate of progression through S phase in S. cerevisiae in Response to DNA damage Amanda G. Paulovich, Leland H. Hartwell · Cell Open access	Sep 1995	596
31	Mapping the Pathogenesis of Periodontitis: A New Look Kenneth S. Kornman · Journal of Periodontology	Aug 2008	595
32	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial Henry Miles Prince et al. · The Lancet	7 Jun 2017	593
33	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial Nancy U. Lin et al. · Journal of Clinical Oncology Open access	29 May 2020	558
34	Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index Robert P. Lyon, Tim D. Bovee, Svetlana O. Doronina et al. · Nature Biotechnology	15 Jun 2015	557
35	Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity Svetlana O. Doronina, Brian A. Mendelsohn, Tim D. Bovee et al. · Bioconjugate Chemistry	22 Dec 2005	522
36	Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates Stephen C. Alley, Dennis R. Benjamin, Scott C. Jeffrey et al. · Bioconjugate Chemistry	Mar 2008	474
37	Estimating effective population size and mutation rate from sequence data using Metropolis-Hastings sampling. Mary K. Kuhner, Jon Yamato, Joe Felsenstein · Genetics Open access	Aug 1995	469
38	Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates Robert P. Lyon, Jocelyn R. Setter, Tim D. Bovee et al. · Nature Biotechnology	7 Sep 2014	464
39	Antibody-Drug Conjugates for Cancer Therapy Paul J. Carter, Peter D. Senter · The Cancer Journal	May 2008	433
40	Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study Robert Louis Coleman et al. · The Lancet Oncology	9 Apr 2021	410
41	Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1) Messoud Ashina, Joel R. Saper, Roger K. Cady et al. · Cephalalgia Open access	19 Feb 2020	405
42	Efficacy and safety of eptinezumab in patients with chronic migraine Richard B. Lipton, Peter James Goadsby, Jeff Smith et al. · Neurology Open access	24 Mar 2020	404
43	Potent antibody drug conjugates for cancer therapy Peter D. Senter · Current Opinion in Chemical Biology Review	5 May 2009	402
44	Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma Robert Chen, Ajay K. Gopal, Scott E. Smith et al. · Blood Open access	18 Jul 2016	399
45	Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate Nicole M. Okeley, Jamie B. Miyamoto, Xinqun Zhang et al. · Clinical Cancer Research Open access	19 Jan 2010	392
46	SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML May S.K. Sutherland, Roland B. Walter, Scott C. Jeffrey et al. · Blood	14 Jun 2013	392
47	Efficient Cancer Therapy with a Nanobody-Based Conjugate Virna Cortez‐Retamozo, Natalija Backmann, Peter D. Senter et al. · Cancer Research Open access	15 Apr 2004	382
48	Pyrimethamine–sulfadoxine resistance in Plasmodium falciparum: what next? Carol Hopkins Sibley, John E. Hyde, Paul F. G. Sims et al. · Trends in Parasitology Review	Dec 2001	371
49	Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides Michael M. C. Sun, Kevin S. Beam, Charles G. Cerveny et al. · Bioconjugate Chemistry Open access	Sep 2005	369
50	Direct Evidence for the Presence of Epstein-Barr Virus DNA and Nuclear Antigen in Malignant Epithelial Cells from Patients with Poorly Differentiated Carcinoma of the Nasopharynx George Klein, Beppino C. Giovanella, Tomas L. Lindahl et al. · Proceedings of the National Academy of Sciences Open access	Dec 1974	362

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.